Biofrontera Inc (BFRI)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Biofrontera Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

Biofrontera Inc is a biopharmaceutical company that develops and commercializes pharmaceutical products for treating dermatological conditions through photodynamic therapy. The company sells Ameluz, a prescription drug, and RhodoLED lamp devices directly to dermatology offices in the United States for treating actinic keratosis, a common pre-cancerous skin condition.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Biofrontera Inc stock.

Our verdict on BFRI

Undervalued: intrinsic value $2.63 per share, market price $0.59, margin of safety 77.6% (as of 2026-11-17).

A 1.1x revenue multiple, discounted for its losses, values the shares at $2.63; the price of $0.59 is 78% below that value.

ETFs with the most weight in BFRI

More on BFRI

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Is BFRI undervalued or overvalued?

BFRI is undervalued (as of the 2026-11-17 close). A 1.1x revenue multiple, discounted for its losses, values the shares at $2.63; the price of $0.59 is 78% below that value.

What is the intrinsic value of BFRI?

$2.63 per share (as of the 2026-11-17 close), against a market price of $0.59. That is a margin of safety of 77.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.